title: LDL immunization induces T-cell-dependent antibody formation and protection against atherosclerosis.
abstract: Atherosclerosis is an inflammatory disease, and the involvement of immune mechanisms in disease progression is increasingly recognized. Immunization with oxidized low density lipoprotein (LDL) decreases atherosclerosis in several animal models. To explore humoral and cellular immune reactions involved in this protection, we immunized apolipoprotein E knockout mice with either homologous plaque homogenates or homologous malondialdehyde (MDA)-LDL. Immunization with both these antigen preparations reduced lesion development. The plaques contained immunogen(s) sharing epitopes on MDA-LDL, MDA-very low density lipoprotein, and oxidized cardiolipin. This shows that a T-cell-dependent antibody response was associated with protection against atherosclerosis. The protection was associated with specific T-cell-dependent elevation of IgG antibodies against MDA-LDL and oxidized phospholipids, and the increased titers of IgG antibodies were correlated with decreased lesion formation and lower serum cholesterol levels.
authors.affiliation: Centre for Molecular Medicine and King Gustaf V Research Institute, Karolinska Institutet, Stockholm, Sweden.
authors.forename: X
authors.initials: X
authors.lastname: Zhou
authors.forename: G
authors.initials: G
authors.lastname: Caligiuri
authors.forename: A
authors.initials: A
authors.lastname: Hamsten
authors.forename: A K
authors.initials: AK
authors.lastname: Lefvert
authors.forename: G K
authors.initials: GK
authors.lastname: Hansson
mesh_terms: D000818:Animals; D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B / Q000276:immunology; D001161:Arteriosclerosis / Q000276:immunology* / Q000473:pathology / Q000517:prevention & control*; D007114:Immunization / Q000379:methods; D007074:Immunoglobulin G / Q000096:biosynthesis*; D007075:Immunoglobulin M / Q000096:biosynthesis*; D007279:Injections, Subcutaneous; D008077:Lipoproteins, LDL / Q000008:administration & dosage / Q000276:immunology*; D008079:Lipoproteins, VLDL / Q000008:administration & dosage / Q000276:immunology*; D008297:Male; D008315:Malondialdehyde / Q000008:administration & dosage / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D010084:Oxidation-Reduction; D010743:Phospholipids / Q000276:immunology / Q000378:metabolism; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D053299:Apolipoprotein B-100; D053283:Apolipoprotein B-48; D001055:Apolipoproteins B; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D008077:Lipoproteins, LDL; D008079:Lipoproteins, VLDL; D010743:Phospholipids; D008315:Malondialdehyde